Cardiovascular Care

MDCO-216

MDCO-216 is a complex of dimeric recombinant apolipoprotein A-1 Milano (ApoA-1 Milano) and a phospholipid (POPC) and is currently under development for the reduction of atherosclerosis and clinical events in acute coronary syndrome (ACS) patients.  

For information on ongoing clinical trials click here.

 

PCSK9si 

PCSK9si is an RNAi therapeutic that utilizes Alnylam Pharmaceuticals’ proprietary Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA conjugate delivery platform. It is currently being developed to lower the synthesis of PCSK9 levels and reduce LDL-C levels.

For information on ongoing clinical trials click here.

 

The above investigational agents are not approved for commercial use in any market; the safety and efficacy of these investigational agents have not been evaluated by any regulatory authority for the uses described.

Global Medical Information

The Global Health Science Center (GHSC) Medical Professionals are available to answer your medical information requests, or receive adverse event reports, other safety related information, and product complaints. 

Please click below to contact the Global Health Science Center.

CONTACT US

Alternatively, adverse events may be reported to the FDA MedWatch Reporting System by phone at 1 800 FDA 1088 (1 800 332 1088) or by mail using Form FDA 3500 at www.fda.gov/medwatch